Citadel Advisors’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,500
| Closed | -$990 | – | 15619 |
|
|
2024
Q2 | $990 | Sell |
1,500
-19,500
| -93% | -$12.1K | ﹤0.01% | 13883 |
|
|
2024
Q1 | $12.7K | Buy |
21,000
+16,260
| +343% | +$9.97K | ﹤0.01% | 13352 |
|
|
2023
Q4 | $2.79K | Sell |
4,740
-7,718
| -62% | -$4.64K | ﹤0.01% | 13658 |
|
|
2023
Q3 | $8.3K | Buy |
+12,458
| New | +$15.3K | ﹤0.01% | 13200 |
|
|
2023
Q2 | – | Sell |
-2,823
| Closed | -$25.7K | – | 15443 |
|
|
2023
Q1 | $25.7K | Sell |
2,823
-2,334
| -45% | -$33.1K | ﹤0.01% | 12865 |
|
|
2022
Q4 | $60.5K | Buy |
5,157
+37
| +0.7% | +$653 | ﹤0.01% | 11903 |
|
|
2022
Q3 | $108K | Sell |
5,120
-30
| -0.6% | -$809 | ﹤0.01% | 11021 |
|
|
2022
Q2 | $125K | Buy |
5,150
+1,013
| +24% | +$34.5K | ﹤0.01% | 11172 |
|
|
2022
Q1 | $206K | Sell |
4,137
-1,130
| -21% | -$55.8K | ﹤0.01% | 11470 |
|
|
2021
Q4 | $370K | Sell |
5,267
-2,153
| -29% | -$181K | ﹤0.01% | 10437 |
|
|
2021
Q3 | $692K | Sell |
7,420
-260
| -3% | -$24.7K | ﹤0.01% | 9104 |
|
|
2021
Q2 | $772K | Sell |
7,680
-1,647
| -18% | -$161K | ﹤0.01% | 9038 |
|
|
2021
Q1 | $870K | Buy |
9,327
+4,167
| +81% | +$423K | ﹤0.01% | 8445 |
|
|
2020
Q4 | $426K | Sell |
5,160
-2,073
| -29% | -$177K | ﹤0.01% | 8437 |
|
|
2020
Q3 | $621K | Buy |
7,233
+5,503
| +318% | +$641K | ﹤0.01% | 6902 |
|
|
2020
Q2 | $161K | Sell |
1,730
-1,233
| -42% | -$67.9K | ﹤0.01% | 8693 |
|
|
2020
Q1 | $84K | Buy |
+2,963
| New | +$115K | ﹤0.01% | 8746 |
|
Citadel Advisors's VBIV Position: Q3 2024 in Review
Citadel Advisors sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 23,651 shares — an estimated $15.6K sold.
Citadel Advisors first reported a position in VBIV in Q1 2014 and held it in 20 quarters. The position peaked at $6.46M in Q2 2021. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.
- Citadel Advisors reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
- Citadel Advisors sold 23,651 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $15.6K.
- Citadel Advisors first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2014 and held it in 20 quarters.
- Citadel Advisors's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $6.46M in Q2 2021.
- 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.